10 Most Admirable Women Leader in Biotech for 2021

NOVEMBER ISSUE 04 2021

0

Most

#Closingthegap The Gradual Rise of Women in STEM Fields

Admirable

Women

Leaders in

New Horizons Top Tech Trends Shaping the Biotech Industry

Biotech

for 2021

LEE ANN

KIMAK

Committed to Saving Lives through Exemplary Leadership

Whenever Suppressed, 'She' Rose!

I

“

do not know what I may appear to the world, but to myself, I seem to have been only like a boy playing on the sea-shore and diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all undiscovered before me.”

her findings by giving her the credits that were long due.

She was a woman who changed science.

Likewise, multiple women are fighting against the odds and making a big difference in the biotech industry. They have ensured that the momentum doesn't die out. Women have worked with passion, zeal, and an innovative approach.

In this quote, Sir Isaac Newton believes that even though our knowledge of the universe has expanded, it still stands on the shore of the 'Great Ocean of Truth'. We are yet to uncover the tiniest part of the wonders the universe holds.

As this awareness is growing, the biotech industry is taking strides to encourage and represent women within the industry.

But more importantly, there seems to be a strong desire in humans to constantly expand this body of knowledge because of the historical scientific wonders achieved so far.

From cloning of 'Dolly the Sleep' to 'Resurrection of Species,' biotechnology has made it possible to discover great marvels of science to be specific.

In this edition, 10 Most Admirable Women Leaders in Biotech for 2021, Insights Care has enlisted women who have significantly impacted the biotech industry. By highlighting this, I believe it is important to note that women are not just demanding space in the industry anymore. They are taking it.

One such wonder was the discovery of mobile genetic elements done by Dr Barbara McClintock in the year 1951.

Her research on plant breeding and genetic engineering made her win the noble prize in Physiology, in 1983.

We're proud to present these 10 women who inspire, lead, and rebuild the Biotech industry. To know more about them, kindly scroll through.

That's around three decades later!

Also, don't forget to go through the articles written by our in-house editorial team and a piece of CXO advice.

Well, why do you think so?

Dive in to have a happy read!

Dr McClintock's work was 'ignored' for many years by her peers in the scientific community. In the face of such resistance, she stopped trying to convince people about her discoveries but never stopped pursuing her theories.

Until a decade after her discovery, the scientific community began to come up with the same conclusions and validated

-Shrutika Khedekar

e.

s and ave ve .

aking

in ho

ead, them,

our

dekar

Editor’s Note

CONTENTS

Articles 24

38

#Closingthegap

New Horizons

The Gradual Rise of Women in STEM Fields

Top Tech Trends Shaping the Biotech Industry

16

Chia Chia Sun Mindfully Driving the Revolu on in Women's Healthcare

Maree Beare

20

An Ardent Advocate of Digital Transforma on of the Healthcare Industry

28

Natalie Bartlett

34

Chauffeur of Modern Change in the Biotech Industry

Noor Shaker An Ardent Advocate of AI-driven Drug Discovery

Cover Story

08

Lee Ann Kimak

CXO

Commi ed to Saving Lives through Exemplary Leadership

Top 5 trends in Radiology and Imaging

44

Editor-in-Chief Senior Editor

Sumita Sarkar Anish Miller

Managing Editor

Abhishaj Sajeev

Assisting Editors

Trishika, Shrutika

Visualiser Art & Design Head Co-designer Art & Picture Editor Business Development Manager Marketing Manager

David King Rohil Shinganapurkar Paul Belin Mrunalinee Deshmukh Amy Jones John Smith Sarah Wilson, John Smith, Alex Vincent

Business Development Executives Sales Executives

Kelli, Bill, Anna

Technical Head Assistant Technical Head Technical Consultants

Jacob Smile Pratiksha Patil David, Robert

Digital Marketing Manager Assistant Digital Marketing Manager SME-SMO Executives

Alina Sege Amol Wadekar Atul, Gemson

Research Analyst Circulation Manager

Eric Smith Tanaji

sales@insightscare.com

November, 2021 Corporate Offices: Insights Success Media Tech LLC

Insights Success Media and Technology Pvt. Ltd.

555 Metro Place North, Suite 100,

Office No. 22, Rainbow Plaza, Shivar Chowk,

Dublin, OH 43017, United States

Pimple Saudagar, Pune, Maharashtra 411017

Phone - 302-319-9947 Email: info@insightscare.com For Subscription: www.insightscare.com

Follow us on :

Phone - India: 7410033802, 74100058552 Email: info@insightscare.com For Subscription: www.insightscare.com

www.facebook.com/InsightsCare/

https://twitter.com/Insightscare

Copyright © 2021 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success.

Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd.

ed or

td.

10 Most Admirable Women Leaders in Biotech for 2021 Featuring

Company Name

Description

Vor Biopharma

Vor Biopharma is a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

Anna Barry, COO

Korro Bio, Inc.

Korro Bio’s team of experts is working to overcome the challenges that have limited existing gene editing and gene therapy approaches, and treat diseases that have previously been unreachable by other methods.

Athena M. Countouriotis, CEO

Turning Point Therapeutics, Inc

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

Chia Chia Sun, CEO and Co-founder

Damiva

Damiva is the women's health company that makes 100% natural products for women’s health and beauty at any age.

Bloody Good Period

Bloody Good Period is now a charity, with a vision to achieve menstrual equity - where the simple fact of bleeding doesn't stop anyone from participating fully in society or life.

Bavarian Nordic

Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines.

Maree Beare, Founder and CEO

Wanngi

Wanngi is a health management app that allows you to track symptoms, immunisations, set medication reminders and manage medical and fitness information, in one secure HIPAA Compliant online location

Natalie Bartlett, Enterprise Business Development

Zageno

ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its awardwinning, first-of-its-kind e-commerce platform.

Noor Shaker, Senior Vice President, and General Manager

Glamorous AI

GlamorousAI is bringing drugs to every target though its AI-first SaaS platform for drug discovery, RosalindAI.

Vipul Singh, Director and COO

Mesa Biotech

Mesa Biotech is a healthcare test and data company that provides actionable information through trusted, PCR-based infectious disease testing—anytime, anywhere.*

Amy Mendel, Chief Legal Officer

Gabby Edlin, CEO

Lee Ann Kimak, US Commercial Lead

10 Most Admirable Women Leaders in Biotech for 2021

LEE ANN

KIMAK

Committed to Saving Lives through Exemplary Leadership

“

“

Our industry is fueled on a constant stream of discovery which requires talented and creative research teams as well as the functions needed to bring new products to market.

hip

A

COVER STORY

“

Lowering the risk of infectious disease for the greater good of our global community is our main mission.

cruc succ

Lea orga may qua rega deci resp

We such Wom som ston thro

One Kim

Lee Com mar prev vacc opp

“Ha the and chal incl enri

Lee Ann Kimak US Commercial Lead Bavarian Nordic

A

s the business world continues to evolve and disrupt, so does the need for efficient and impactful leadership. As evident as it could be, leadership is crucial to a company’s ascension towards the zeniths of success.

Leadership is an integral part of running any successful organisation – large or small. The type of leadership needed may differ depending on what industry you’re in. Still, the qualities of a good leader remain similar regardless—having strong interpersonal skills, being decisive yet open-minded, knowing when to delegate responsibility appropriately, and leading through example.

We at Insights Care are on a ceaseless endeavour to seek such impactful leaders. In this edition—10 Most Admirable Women Leaders in Biotech for 2021—we came across some of the most accomplished women who’ve left no stones unturned when it comes to inspiring the world through their journey towards excellence.

One prominent name among such leaders is Lee Ann Kimak, the US Commercial Lead at Bavarian Nordic.

Lee Ann joined Bavarian Nordic in January 2020 as the US Commercial Lead following the acquisition of two marketed vaccines from GSK. The ability to leverage her previous experience in vaccines and the integration of vaccines into a company made this an interesting opportunity for her.

“Having the opportunity to build a US organisation from the beginning—building a team, establishing the processes and infrastructure needed to be successful—was an exciting challenge for me. The company leadership and culture are inclusive, collaborative, and agile, which makes it an enriching working environment,” says Lee Ann.

“

Setting Benchmarks Bavarian Nordic is a fully integrated vaccines company focused on developing, manufacturing, and commercialising life-saving vaccines. The company’s fundamental mission is to save and improve lives by unlocking the immune system’s power.

“We have established a bold vision and aspiration to become one of the largest pure-play vaccine companies by 2025,” says Lee Ann. Bavarian Nordic has a strong heritage in vaccine research and development and proven successful technology.

Innovation remains a cornerstone in developing a strong product pipeline to help fight existing and emerging diseases around the globe.

Overcoming Adversities We asked Lee Ann about the challenges that the COVID-19 pandemic imposed on the global biotech industry and Bavarian Nordic and how she and her team pivoted to surpass those challenges. Her response: The pandemic has spurred global leadership to look to biotechnology and pharmaceutical companies for solutions to the pandemic, including diagnostics, assays, therapeutics, and vaccines.

Our industry is uniquely suited for this task as we have invested in scientific acumen and the regulatory, clinical, and manufacturing capabilities to deliver these needed solutions.

“The global COVID-19 pandemic did, unfortunately, impact many parts of our business. However, a highlight earlier this year is that Bavarian Nordic reported encouraging preclinical data for a COVID-19 vaccine candidate ahead of first-in-human trials.”

Good business is about hiring good people; without them, it is hard to grow and sustain momentum over time.

“The pandemic also caused business challenges to collaboration, hiring and of course travel and interactions with customers. Bavarian Nordic took complete care to assure that appropriate precautionary measures are in place and consistent communication and check-ins with our team members occur.”

needed to bring new products to market. Our organisation is learning how to identify the most creative and talented teams to focus on bringing innovative products to market, like an RSV vaccine and COVID booster. When you give a great team the job of working on these life-saving products and the tools to do it, they can change the world! You’re doing something useful for society, which is an incredible thing.”

Voy

A Necessary Change

Talk ope Bav vacc mar year dise RSV

Opinions that Matter

When asked, what would be things she would change about the global biotech industry, Lee Ann expressed, “The pandemic spurred intense government, media, and public attention on biotech. Maintaining a high level of innovation and development is critical to the success of our industry, but we also need to have highly skilled talent in other areas beyond discovery and development.”

“Go it is goa outs effe for t con

We asked Lee Ann for her opinion on the necessity for biotech companies to align their offerings with newer technological developments, which she answered saying, “As I mentioned before, Bavarian Nordic has a strong heritage in vaccine research and development, and with a proven technology, innovation remains a cornerstone in the development of a strong product pipeline to help fight existing and emerging diseases around the globe.”

“We need to focus on building and retaining good talent, managing complexity, and improving commercial and development execution. Bringing good products and vaccines to approval is only part of the process. We need to make sure that we are doing the market development and otherwise providing the commercial support to assure that valuable products are accessible to the patients who can benefit from them.”

“We are experts in live virus vaccine manufacturing, and with the recent addition of fill and finish capabilities, we have enabled end-to-end commercial-scale manufacturing.

Lowering the risk of infectious disease for the greater good of our global community is our main mission,” she expressed.

Bequeathing the Keys to Excellence

“Our top priority is the safety and wellbeing of our team members, customers, and communities we serve. We immediately moved to remote working, and like many companies, became accomplished at leveraging team platforms to collaborate, hire talent, and interact with customers. Several working groups across the globe were formed to evaluate areas of business, including the outlook for our future workplaces and more flexible ways of working,” Lee Ann added.

Sharing her opinion on the probable future of the biotech sector post the pandemic, Lee Ann says, “Our industry is fuelled on a constant stream of discovery which requires talented and creative research teams as well as the functions

“

As an excerpt from her professional journey, Lee Ann shares valuable advice to those aspiring to venture into the Biotechnology space, saying, “Don’t give up easily is one piece of advice. Working in small or start-up biotech’s can be challenging, and there is a new problem to be solved every day. Resilience needs to be developed as well as a willingness to operate with a high level of ambiguity and not a lot of processes.”

We have established a bold vision and aspiration to become one of the largest pure-play vaccine companies by 2025.

n is

Voyaging towards New Horizons

t, ea cts

Talking about her vision for scaling Bavarian Nordic’s operations and competency, Lee Ann says, “Currently, Bavarian Nordic’s RabAvert is the market leader in rabies vaccination, and we look forward to adding additional market-leading products to our portfolio in the coming years. We have multiple product candidates for infectious diseases and cancer, including candidates for COVID and RSV, which are large scale programs.”

e

out

c ion y, eas

to d at

he e an

d

“Good business is about hiring good people; without them, it is hard to grow and sustain momentum over time. My goal is to build on our existing team by adding more outstanding talent that can make sure we effectively deliver these products to the market for the patients who need them,” Lee Ann concludes.

Stay in touch.

Subscribe to Insightscare Get Insightssuccess Magazine in print, & digital on www.insightscare.com

Check should be drawn in favor of : INSIGHTS SUCCESS MEDIA TECH LLC

Chia Chia Sun Mindfully Driving the Revolution in Women’s Healthcare

Our mission is to develop products that are helping, not harming, women with a focus on prevention.

Chia Chia Sun CEO and Co-founder

M

indi hav in th igno and ove abo the

One peo wom is C foun

In th Sun the face pan firm

Giv jour tell into Abo peri -Ir didn futu the of k wom our

I sta drug vag ther to u con toxi natu Dam incl who train real exis

16|November 2021|www.insightscare.com

s

10 Most Admirable Women Leaders in Biotech for 2021

M

odern science and the perseverance and contribution of several individuals towards women’s health have made some significant discoveries in the sector. The negligence and ignorance regarding women’s health and wellness are now being slowly overcome as people have begun to talk about it and break the stigma around the topic.

One prominent name on the list of people striving relentlessly to improve women’s health by leveraging science is Chia Chia Sun, the CEO and Cofounder of Damiva Inc. In the following interview, Chia Chia Sun talks about her inspiring journey in the women’s health arena, how she faced the challenges arising from the pandemic and the prospects of her firm.

Give us a brief overview of your journey as the CEO of Damiva and tell us what inspired you to venture into the women's health space.

About ten years ago, when I was perimenopausal - I'm menopausal now - I realized that there was so much I didn't know about myself and my future menopause. I was stunned by the lack of information - and my lack of knowledge - about the stages of a woman's life, our hormonal fluxes, and our bodily changes.

I started Damiva after a trip to the drugstore, looking for a product for vaginal dryness. What I found was that there was absolutely nothing I wanted to use because all the products contained so many chemicals and toxins. After formulating a 100% natural product - called Mae by Damiva - with several partners, including my husband Gardiner Smith, who is a protein chemist and lawyer by training, and a couple of stints on reality TV shows, Damiva came into existence.

It became my passion and life mission to develop products for women that are good for us for a lifetime, and we can use them at any age. I decided that, due to the dire unmet need, I would only work in women's health for the rest of my career.

Tell us more about Damiva, its vision, and the key aspects of its expertise in health and wellness.

The core vision for Damiva is to create products that are good for women. To us, this means 100% natural feminine care and skincare products that are pH balanced for each stage of life and - as a priority - do not contain any chemicals that are toxic, disrupt hormones, and contribute to the climate crisis.

Creating an all-natural, shelf-stable product is much harder than you might imagine (think Buzzfeed's Burger Experiment). So, we have proprietary formulations and patents that speak the unique nature of our health and wellness products. For example, by removing water from our formulations, we don't need to use chemical preservatives and can still maintain a shelf life of three to five years without bacterial growth.

From a leadership perspective, what is your opinion on the impact of the pandemic on the global healthcare sector, and how did you aid your organization to overcome the challenges rooting from the pandemic?

The pandemic focused a lot of attention on the global healthcare sector and helped create more awareness of the need for health care innovation. On the plus side, there is more capital and consumer acceptance and adoption of new health technologies. On the downside, larger companies benefited from the massive shift in public opinion and government funding more than smaller companies.

Our retail revenues were impacted by COVID-19 due to the drop in-store traffic by our retailers such as CVS, Target, and Rite-Aid. We were already expanding our online sales, and we put much more effort into the endeavor as the pandemic unfolded. We realized immediately that the pandemic gave us an opportunity to connect much more closely with our customers, and the learnings have significantly impacted our business and improved our product development.

What is your opinion on the necessity for health and wellness companies to align their offerings with newer technological developments, especially when it comes to catering to the everevolving needs of the industry?

A significant lesson from our expansion of online sales was that our customer is highly sensitive, not just to toxic chemicals in formulations but also to the changing world around us, including technology, information, and macroeconomic factors such as climate change.

Our philosophy at Damiva is to listen to our customers and their needs.

Accordingly, we packaged our next-generation products in discrete sachets (instead of a large bottle), reducing our packaging footprint by over 50%.

We also developed a customer-centric educational membership program that is entirely online and geared to specific life stages.

Regarding the alignment of health and wellness companies with advances in technology, while I'm personally invested in innovation, as the co-inventor on several patents, I believe that the field of women's health needs more than innovation; it needs innovation communication.

17|November 2021|www.insightscare.com

We need to try harder to understand women's needs, even if these conversations are awkward or uncomfortable. We need to break down the taboos that prevent women from expressing their needs. Vera Rubin, who is one of my heroines and should have won the Nobel Prize for Physics as the physicist who discovered dark matter, said it best when she said, "Don't shoot for the stars; we already know what's there. Shoot for the space in between because that's where the real mystery lies."

What efforts did you and your team at Damiva take during the pandemic to sustain operations and ensure the safety of your employees at the same time?

Our team is in Canada, the United States, Europe, and India. While we were accustomed to virtual business already, we made the switch from working exclusively in our Toronto offices to the entire staff working virtually from home during the pandemic.

In your opinion, what could be the future of the women's health space post the pandemic? And how are you strategizing Dative’s operations for that future?

Women are already the ‘Chief Medical Officers’ of our households as 80% of us make the medical decisions for our families. The women's health space is already changing post-pandemic as households are increasingly accustomed to at-home testing, diagnostics, and preventive medicine, with women leading the charge.

The new norm will continue to be more technology, less travel, and more local support for women's well-being.

The cons of a post-pandemic era for women's health are that, while women took on more of a role at home with respect to childcare, children's schooling, and family health, areas

such as career growth and mental health have suffered. To remedy this, we women need to spend some time putting ourselves and our health first.

At Damiva, our future operations postpandemic will focus on prevention, self-care, and the use of technology to deliver highly informative and specialized content.

Our mission is to develop products that are helping, not harming, women with a focus on prevention. As our products are completely natural and pH balanced, they help preserve the skin microbiome and include preventive ingredients such as probiotics that are stable at room temperature.

With respect to self-care, our strategy for 2022 and beyond is to continue to have fun with our products while creating a supportive environment with our online content membership program. For example, we will always have cheeky slogans such as "lip balm for your other lips" for our labial balm.

Now, we will help women understand the different parts of the labia and genital regions and how they change over time.

In response to inquiries from health professionals, we have also started a collaborative Professional Program to work with pelvic health experts, such as menopause practitioners, nurses, physicians, and physiotherapists, to educate women about our products.

If given a chance, what is the one thing that you would change about the global healthcare industry?

I would change the ratio of male to female leaders in the industry.

Depending on the area, female CEOs comprise 3% to 6% of the total number, and this is an appalling statistic.

To quote Vera Rubin again, "Worldwide, half of all brains are in women," and another great quote: "We all need permission to do science, but for reasons that are deeply ingrained in history, this permission is more often given to men than to women."

As an established leader, what would be your advice to the budding entrepreneurs aspiring to venture into the women's health space?

Just go for it! Feet first, as fast as you can. We need many more women to expand this important industry that affects half the human race.

Pertaining to your role as Damiva's CEO, how do you envision scaling your company's operations and offerings in 2022 and beyond?

One of the major initiatives we put into place during the pandemic was to redesign our packaging to withstand a variety of extreme temperatures that we are experiencing with global warming and climate change. This redesign will enable us to grow quickly and scale our operations in North America and beyond. We are partnering at home here in the U.S. with our manufacturer to be the largest 100% natural women's health company globally.

First and foremost, as always, our offerings continue to put women first by giving women what we need and want: completely natural, vegan, ethical, and sustainable products that are free of hormone disruptors and toxins.

18|November 2021|www.insightscare.com

n We ut d in n

uld

ou

a's g

into

da t

ckly

gest any

st d

at

M

heal scre hav and this adv tech imp for h wor

The pati the plat plat The man man plat Ma entr Wa com

Founder and CEO

Maree Beare An Ardent Advocate of Digital Transformation of the Healthcare Industry 20|November 2021|www.insightscare.com

Mar Hea has wom Hea inno glob exec proj gov brin and heal sect

The Clin

In 2 she con thei acce

e

of ry

10 Most Admirable Women Leaders in Biotech for 2021

M

odern hospitals and clinical institutions have become increasingly reliant on healthcare software systems. Touch screens, tablets, and internet reports have quickly replaced paper-based files and written patient information. All of this has been made possible by huge advances in the realms of information technology. Technological improvements have made life easier for hospital administrators around the world.

The requirement for a comprehensive patient information system spawned the concept of healthcare management platforms. The primary focus of these platforms is managing patient records.

The demand for healthcare management solution is attracting many entrepreneurs to develop such platforms. To cater to this demand, Maree Baeree an enthusiastic entrepreneur established her companies Wanngi and Clinials, to track and communicate the health of people.

Maree Beare is a sector leader in HealthTech, Femtech, and Biotech, and has been listed by Forbes in the top 50 women-led startups disrupting Healthtech. She has over 30 years innovation experience, navigating global software companies and executed many large and high-profile projects to meet company and government strategy. Maree now brings this leadership to the Startup and Innovation sector and the healthtech, femtech, and biotechnology sectors globally.

I imagine a world where people could improve their chances of being diagnosed by providing their health history to the various doctors and hospitals they might see during their life.

imagined a world where people could improve their chances of being diagnosed by providing their health history to the various doctors and hospitals they might see during their life,” says Maree.

Maree is of the opinion that hospitals and doctor’s health systems are not connected, resulting in people having to repeat their health history over and over at each health appointment leading to miscommunication and misdiagnosis.

Fast forward to 2020, Maree’s husband went on a clinical trial and was required to report any adverse events by completing a paper form. Opening Maree’s eyes to the issues with participating on clinical trials where lifesaving treatments are not making it to market as 80% research trials fail to find enough people.

In 2021, Maree launched Clinials, providing efficiencies in the $47 Billion clinical trials market by disrupting the existing study participant recruitment process, so people are getting access to more effective treatment sooner. “We aim to Enhance patent recruitment per clinical trial to improve site economics for clinical trials leading to Improved treatment and patient outcomes and for many, this means improving life quality (QALY),” shared Maree.

Braving the Pandemic During the outbreak of the COVID-19 pandemic, Maree and her team switched to working from home and returned to the office only when officials allowed. Maree believes that the pandemic has sped up innovation in healthcare due to the dire necessity. It led to the increased use of telehealth for safety and convenience of continued care.

The Inception Story of Wanngi and Clinials In 2017, Maree created Wanngi when she realized that it was a problem for consumers to make decisions about their own health when they had no access to their own health data. “I

21|November 2021|www.insightscare.com

outcomes for society as a whole,” adds Maree.

Maree aspires to overthrow the misconception that investment cycles in healthcare are the same as traditional investments. “History tells us that it takes 10 years to be an overnight success in Healthtech,” she added.

Envisaging Future Endeavors The pandemic has escalated the need for decisions around a person’s health status and the requirement for access to COVID-19 test results and vaccination status. There’s a great deal of noise and uncertainty about accessing this data for consumers.

However, Wanngi is fit for purpose as a consumer personal health record, so it was ready and able to store and provide evidence of COVID-19 tests and continues to help people provide their health history during a telehealth appointment.

However, with the focus on COVID19, the health management of people with chronic illness declines and the aftermath of pandemic will see a burden of late-stage chronic illness on the healthcare system. Clinials will provide the platform to connect these

patients to any clinical trial relevant to their health conditions, where they meet the inclusions and exclusions of the study.

Leveraging Technology When asked for her opinion on the importance of technology in the healthcare industry, Maree says, “Companies seek to be economically sustainable, and healthcare is no exception. Technology will drive efficiencies in healthcare as well as improving patient outcomes with AI and innovation, and in the future, it will continue to develop in dramatic ways.”

“While we can take a glimpse and debate the details of future trends in healthcare, we need to be clear about the drivers so we can align with them and actively work to ensure the best

Clinials is uniquely positioned to secure product led growth moving forward into 2022 and beyond. Having raised pre-seed funding in 2021 and preparing for a larger raise in early 2022, the company is ready to expand the team to support its customers. It is focused on building the innovation roadmap to decrease cost of trial marketing, recruitment and leveraging Machine learning and AI to accelerate product-led growth and continue Clinials customer retention.

“I have already delivered on the future strategy by launching Clinials this year in response to the opportunities of Australia being relatively COVID-19 free, and there being a verified problem to solve with participant recruitment in clinical trials to enable Australia to be globally competitive in research of new treatments,” concludes Maree.

22|November 2021|www.insightscare.com

dds

es onal

ing

nd is

ng ate

ure ear

9 lem t in be

S

dev driv

As a subs ven resu univ dev

As e STE grad rela

Res far l mai mal

24|November 2021|www.insightscare.com

#Closingthegap

The

Gradual Rise

Women of

in

STEM Fields

S

cience, technology, engineering, and mathematics (STEM) fields are significantly important to power innovative advancements and enhance technological developments. These are the factors that in turn are seen as drivers of social and economical growth.

As a result, researchers and policymakers are paying substantial attention to analyse and promote high-growth ventures in STEM fields. The consistent analysis has resulted in making STEM a valuable part of education in universities and also in the accommodation of jobs in developing countries.

As every coin has two sides, one of the major criticisms of STEM has to do with the gender disparity in students who graduate with STEM degrees and enter career mainstreams related to these fields.

Research data has conventionally displayed that 'women are far less likely to graduate with a STEM degree or enter a mainstream career in this field,' when compared to their male opposite number.

Vanquishing a Gender Gap Proponents of closing this gender gap in the STEM field points out that this gap not only reflects unfair conditions and poor treatment of women in this field. Furthermore, it also reduces the quality of work and innovations being extracted from these fields.

It is a subject of recommendation and facts that indicate scientific progress relies on unique solutions that are emerging from different perspectives. Closing the gender gap make STEM fields more diverse, also, redefines the assurance of problem-solving approaches with a variety of different perspectives.

Although the broad gender gap that exists across the STEM fields becomes a topic of discussion, there is a great deal of variety among different STEM subfields when it comes to the exact scale and nature of this gap.

Some subfields have no gap at all and favour women in graduation, and job placement. In subjects like social science, there is a greater number of women if compared to men, and it remains strongly favourable towards women.

25|November 2021|www.insightscare.com

Enabling Innovations It is a fact of assurance that women would benefit from the creation of more inclusive atmospheres in STEM fields, these fields as a whole can become more engaging.

A field like science works and functions at its best when it considers a wide range of diverse perspectives. By excluding women, such fields not only exclude a wide range of extremely talented future leaders but also fresh perspectives that could be used to create innovative approaches to resolve problems.

Engaging women in stem fields has improved the quality of work being executed in those fields and it has opened up distinguished career opportunities for women.

In general, research has displayed that, 'diverse workplaces are happier in nature and more productive,' indicating that STEM organizations could do better for themselves by being more inclusive.

Breaking the Stereotypes The idea of the gender equality paradox is not without its problems. Critics point out that countries with poor representation in STEM fields have a long history of excluding women from science and mathematics, which has been deeply embedded into the culture that surrounds young girls as they are growing up.

They also point out that there is no gap in ability since researchers found that girls performed as well or better than boys on STEM tests in most countries.

True solutions to the gender gap in STEM fields work on multiple levels. Exclusion begins in childhood, when young girls have been pushed away from creative fields like science, and mathematics, and are encouraged to adopt more care-oriented work.

This scenario is drastically changing as parents are encouraging and reminding their children that they can grow up to do anything that they want. Parents are also providing a wide range of opportunities for children to explore their interests, including those related to STEM, such as coding camps and science fairs.

In education, scholarships and grants are striving hard to bring women into STEM departments. However, these departments must do everything in their power to prevent discrimination and sexism against female students to improve preservation rates.

In the workplace, employees must identify and address the discrimination in their hiring practices so they can generate a diverse workplace that enhances productivity among their employees.

Outside of school and the workplace, broader societal changes are also called for. Women are often harder hit by a couple's decision to raise a family, forcing them to take more time off of work during critical periods in their careers, such as early on at a new job or even during their doctoral studies.

Despite these situations, women are making noteworthy progress not only in STEM fields, but also in their profession, and are breaking the stereotypes.

The Profound Leaders in STEM Many women have made significant contributions to our understanding of the world and these contributions are now being recognized as an example for the young generation.

Below are just a few of the women who have changed the world with their knowledge and expertise in STEM fields.

Ada Lovelace Ada was one of the early computer scientists. Her work was instrumental to the advancements of early computer science as she developed an algorithm for Charles Baggage's analytical engine that would output Bernoulli numbers.

Marie Curie Marie Curie is recognized as the most inspirational female scientist of all time. She was the first person to win the Noble Price twice in her career. Marie's work involved radioactivity, including the discovery of a few radioactive elements.

Rosalind Franklin Rosalind was an English chemist whose work on molecular structures established a foundation of our comprehension of the fundamental workings of things like DNA, RNA, and viruses.

Sally Ride Sally Ride was an astronaut, engineer, and physicist. Sally's position as the first American female astronaut and the third woman to travel into space, as well as her science books aimed at children, have created the legacy of an inspirational figure for many young women and girls interested in STEM fields.

The Journey Ahead...

Although increasing comprehensiveness for women in STEM has recently become a trending topic, women have been making waves in STEM fields since humans began to examine the natural world.

One way to bolster the ranks of future women in STEM is to acknowledge the contributions women have made in the subfields of STEM in the past.

26|November 2021|www.insightscare.com

- Abhishek Joshi

by a

r

ow n. e s.

was nce

le

e

ular n of d

ly's hird

ve to

is he

oshi

high sam lab tele look

Natalie Bartle Enterprise Business Development

To f biot prom Ent of Z solv com incl com alte mak extr elim Bar clie dev

In th us a saile clie Foll inte

Giv jour ZAG insp biot

Natalie Bartlett Chauffeur of Modern Change in the Biotech Industry

P

harma R&D is one of the most booming industries that always supported the world even when the pandemic hit it; thanks to its bloodline, the leaders of lab supply

chain companies have always kept it running. In the last few years, the biotechnology industry has witnessed digitalization and enhancement of technology in its every code of conduct

as people are looking for an advanced way of coxswaining everything.

The demand for digitalization in the biotechnology supply sector is very

28|November 2021|www.insightscare.com

I sta focu life in a was inte Cata ZAG scie focu

I fou outd supp tech

t

10 Most Admirable Women Leader in Biotech for 2021

high as many are still following the same outdated method of purchasing lab supplies with catalogs, fax, telephones, and so on, and buyers are looking for a better alternative.

To fulfill this need of the biotechnology industry, one of the prominent leaders Natalie Bartlett, the Enterprise Business Development of ZAGENO, has worked very hard to solve many issues through the company's in-depth solutions. These include online monthly spending data, comparison of products, best alternatives, tracking order status, etc., making the industry's procedures extremely convenient. Also, by eliminating various steps, Natalie Bartlett has given her best to save her client's time and money potential by developing the company's top services.

In the following interview, Natalie tells us about the various challenges she sailed through to provide ZAGENO's clients with excellent services.

Following are the highlights of the interview: Give us a brief overview of your journey through your role at ZAGENO, and also tell us what inspired you to venture into the biotechnology sector.

I started working in venture capital and focused on early-stage startups within life sciences and software. Growing up in a family of healthcare providers, this was a good fit because I always had an interest in the space. While at General Catalyst, I sourced and invested in ZAGENO, a startup reimagining life sciences commerce with an initial focus on R&D supplies.

ed

e

I found myself intrigued by how outdated purchasing products for lab supplies was and how a team and technology like ZAGENO's could help

historical spending, detailed product comparisons, and alternatives to products on backorder or with long lead times.

.

solve this. I decided to roll up my sleeves and help make a direct impact on myself. Today, I work on ZAGENO's enterprise business development team, focusing on helping large pharma organizations improve their research efficiency when ordering supplies.

Tell us more about ZAGENO, its vision, and the key aspects of its stronghold in the global biotechnology space.

ZAGENO's vision is to accelerate the time between scientific milestones.

While simple to articulate, it is quite complex in executing this vision. It begins by completely rethinking the industry's lifecycle, which begins with identifying where other business markets have successfully transformed, modernized, and automated. We sometimes take the kernel of other innovations and customize them for biotechnology.

Our interpretation of the wellestablished subscriber model is experienced through ZAGENO's marketplace and services. Through it, our subscribers benefit from various unique advantages such as data on

At a high level, ZAGENO seeks to democratize the buyer-seller relationship through lab supplies - the very lifeblood of scientific discovery.

Historically, this part of the industry was dictated by manufacturers and distributors. Without an alternative, scientists had little choice but to accept this status quo. But just as the subscription economy has redefined the buyer-seller relationship in consumer markets, so is it changing these relationships in biotechnology.

The future of the industry will be a more harmonious one, equally dictated by manufacturers and users. Because ZAGENO provides a platform to support this evolution, we are at the epicenter of this change.

From the business development perspective, what is your opinion on the impact of the pandemic on the biotech space? How did you aid your organization to overcome the challenges rooting from the pandemic?

From ZAGENO's perspective, the pandemic has divided the industry into groups of haves and have nots. The thing that is often overlooked is the running cost of biotech, which can range from $10,000-40,000 per day.

So, any downtime in productivity can have profound business implications to the bottom line.

COVID's impact on the supply chain caused some labs to go dark and their scientists to be furloughed. But biotechs that subscribe to ZAGENO benefit from access to a marketplace

29|November 2021|www.insightscare.com

We the whi futu

Afte labs beg spli perf man

where they are able to forecast accurately and manage supply levels and face challenges like backorders and extended lead times with suitable alternatives to ensure labs remain open and productive.

What is your opinion on the necessity for biotech companies to align their offerings with newer technological developments, especially when catering to the everevolving healthcare needs?

While focusing on investing in earlystage startups at the intersection of life sciences and software at General Catalyst, I witnessed the burgeoning of startups looking to accelerate the drug discovery process from R&D through clinical and beyond.

In my opinion, the software has not impacted the life sciences field in the same way it has in other industries, so the opportunity to accelerate the drug discovery process (which today averages ten years) through the use of the software is immense.

For R&D purchasing in particular (ZAGENO's focus), a vast majority of

research scientists are still purchasing supplies in the same way consumers purchased goods in the 1970s! They are still phoning and faxing in orders via paper catalogs. While today's consumers can buy groceries in one click and have them arrive the same day, scientists spend 4-8 hours just finding and purchasing supplies. If technology can reduce wait times from weeks to days and even hours, imagine the savings potential, both in time and money, of the drug development process at large!

Through your role as Enterprise Business Development, what efforts did you and your team at ZAGENO take during the pandemic to sustain operations and ensure the safety of your employees at the same time?

As you may imagine, the demand for R&D supplies during COVID has been immense. As our team transitioned to a work-from-home setup, our order volume simultaneously skyrocketed.

Personally speaking, I cannot imagine starting a new role or even a first job completely remote! But with half of ZAGENO based in Berlin, we were

already accustomed to remote collaboration through video meetings, slack, and other web-based tools. To further support a work-from-home environment, our team also focused on several initiatives, such as new daily and weekly stand-up meetings.

We also provided our leadership with resources for remote management and guidelines for remote work to all employees. To provide additional support for new employees, we established a buddy system so that new hires had a dedicated ZAGENO alum as a resource. For all employees, ZAGENO also sent care packages to ensure everyone had proper at-home office and technology setups.

Despite a majority of ZAGENO never having met one another, as a company, we have been quite productive, which is evidenced by a doubling in revenue over the past year.

In your opinion, what could be the future of the biotech sector post the pandemic? And how are you strategizing your organization's operations for that future?

30|November 2021|www.insightscare.com

It be supp scie the in p that long even

ZAG to e mob into Mea cust to su they

gs, o

on y

th nd

We have witnessed a few trends during the pandemic for remote lab work, which I believe will continue in the future.

As an established leader, what would be your advice to the entrepreneurs aspiring to venture into the biotech space?

a particular focus on enhancing their purchasing experience for the industry's largest pharmaceutical companies.

After the initial closure of research labs, we saw that research scientists began to return for critical work only, splitting into teams to reduce risk and performing all operational management remotely.

For entrepreneurs looking to build software companies in the life sciences space, in particular, my biggest advice would be to create a well-rounded team with experience from both the life sciences and software industries.

In this time, I've witnessed the huge trend happening across pharma R&D to provide a superior user experience, consolidate buying channels, and drive digital adoption for both time savings for research scientists and cost savings for the research team at large.

It became even more critical that supplies were there for research scientists when they did spend time in the lab, especially amidst an increase in product backorder rates. I believe that remote lab management will be a long-lasting effect of the pandemic, even beyond just ordering supplies.

Given that startups in this space are still emerging identifying and hiring individuals with blended expertise is quite challenging. However, there is unique knowledge from both sides that needs to be combined in order to build a successful company, so instilling this balance through your team from the start as well as while you grow is essential.

ZAGENO is strategizing its operations to enhance these capabilities through mobile optimization and integration into inventory management solutions.

Meanwhile, our operations and customer success teams are equipped to support research scientists whether they are at the bench or at home.

How do you envision contributing towards the goal of sustaining your company's stronghold in 2021?

Building supply and demand are crucial to winning the market with any new subscriber service (e.g., a marketplace). I believe that working with large pharma will not only drive our stronghold within the market to realize our company's full potential but will also simultaneously bring efficiency to the lengthy R&D drug development process. It's a true winwin, which aligns with ZAGENO's greater mission to accelerate life sciences.

I have recently taken on a role in enterprise business development, with

new m

o e

ver ny, ch ue

e he

31|November 2021|www.insightscare.com

Noor Shaker,

Senior Vice President, and General Manager

A

inte proc proc effic dev com iden

Our focus on hiring self-motivated, highly productive individuals has certainly helped us scale while sustaining healthy growth.

AI a savi cata imp go-t who

Wh the Sen Gla

In a jour of A

Noo you you

34|November 2021|www.insightscare.com

10 Most Admirable Women Leaders in Biotech for 2021

Noor

Shaker

A

midst the ongoing pandemic, AI-driven drug discovery has been at the forefront of the healthcare sector, consisting of molecular features, interactions, and behavior in order to build better materials, processes, and systems for specific purposes. Traditional processes require clinical trials on patients to investigate the efficacy and optimum combination of drugs or dosage in developing viable therapies. But an AI-based drug combination therapy is proving to be a critical technique for identifying optimum and effective regimens.

AI accelerates the drug development process along with saving time, money, and human efforts. In short, it is a catalyst that speeds up drug discovery. Hence, the implementation of AI in the healthcare space has become a go-to option for pharmaceutical companies and their leaders who are aspiring to dominate the drug discovery market.

While many such health leaders are charting strategies for the healthcare sector, we came across Noor Shaker, the Senior Vice President and General Manager of GlamorousAI, who chose to take the unbeaten path.

An Ardent Advocate of AI-driven Drug Discovery

My journey started as a computer science engineer in my home country, Syria. I got fascinated by Artificial Intelligence early on, and I realized that the field would have a great impact on so many aspects of our lives. I, therefore, decided to pursue a career in AI, and that led to my assistant professorship in AI from the Aalborg University of Copenhagen.

The time at which I got my assistant professorship coincided with the heartbreaking passing of my mother after a long fight with lung cancer. Shortly after, I decided to drop my academic position and focus on the translation of AI research to the drug discovery space. I co-founded Glamorous AI in 2020 to deliver on my mission to cure diseases with the power of AI. Tell us more about GlamorousAI, its vision, and the key aspects of its stronghold in the global biotechnology space.

In an interview with Insights Care, Noor sheds light on the journey of her company, its services, and how the adoption of AI is transforming the healthcare sector.

GlamorousAI’s vision is to bring drugs to every disease. We are doing this through innovative AI solutions that are data-efficient and through putting these tools in the hands of drug hunters. Our AI allows us to extract information and patterns about the disease and potential drugs from challenging datasets.

Noor, give us a brief overview of your journey through your role at GlamorousAI and also tell us what inspired you to venture into the biotechnology sector.

This is a key in biomedical research where data is usually noisy, unbalanced, and small. We’ve recently joined forces with X-Chem, a leading service provider in the

35|November 2021|www.insightscare.com

DNA-Encoded Library space, and we believe that together, we can bring AI, data, and expertise under one roof to provide the best services to the pharmaceutical industry.

Our focus on hiring self-motivated, highly productive individuals has certainly helped us scale while sustaining healthy growth.

What is your opinion on the impact of the pandemic on the biotech space, and how did you aid your organization to overcome the challenges rooting from the pandemic?

In your opinion, what could be the future of the biotech sector post the pandemic? And how are you strategizing your organization’s operations for that future?

I think the pandemic had a positive impact on the biotech sector; it certainly increased the public awareness of the field and the difficulties associated with the discovery of new medicines. Glamorous AI’s inception was just after COVID-19 hit, and that meant that we had to build a remote working environment and culture from the get-go. That has actually helped us build a global hiring strategy and tap into the international talent market.

What is your opinion on the necessity for biotech companies to align their offerings with newer technological developments, especially when it comes to catering to the ever-evolving healthcare needs?

I think the biotech industry needs to keep up with the fast pace of innovation to ensure the best outcomes for patients.

Startups and small businesses in this sector are leading the way with innovative solutions that will soon become the mainstream to how we discover and treat patients.

Through your role as SVP and General Manager, what efforts did you and your team at GlamorousAI take during the pandemic to sustain operations and ensure the safety of your employees at the same time?

We have a great multidisciplinary team of international experts located in different geographies. We have been hiring for remote positions since the company’s inception, and that meant that we needed to put processes in place to ensure clear communication and a healthy, scalable culture.

It became evident just over the past year, or so that AI will play a big role in how we develop new cures. AI innovation and adoption in the biotech sector are set to increase over the next few years. I believe success in this sector will be led by organizations who understand the multidisciplinary nature of innovation required and, therefore, the need to build cohesive multidisciplinary teams.

I’m also a believer in open innovation and that AI tools and advancements should be integrated with every drug discovery program. We are therefore focused on not only building best-in-class AI but also on democratizing access to our AI solutions through our SaaS platform, RosalindAI. As an established leader, what would be your advice to the entrepreneurs aspiring to venture into the biotech space?

Personally, I find the biotech sector one of the most, if not the most, exciting fields to be in. It combines the social drive of improving human lives with the intellectual cursory necessary to find innovative ways to advance science.

How do you envision scaling your company’s operations and offerings in 2022 and beyond?

We are looking to enable every drug hunter with the bestin-class AI solutions to drive the discovery of more effective medicines. To deliver on this, we are hiring the best talent and expanding our customer base to enable the democratization of AI in drug discovery.

36|November 2021|www.insightscare.com

g

ch ing

ill ion r e ry

and

y ss AI.

to h

ot

sory

ons

-

e

Top

Tech Trends Shaping the

Biotech Industry B

iotech Innovations: Casting a new net

Pandemic brought Biotech from the shadows to the limelight. The industry which was earlier catering mostly to medicine, biopharma, and healthcare, is now opening for consumers of Biotech and customers of Biotech.

They have already been re-casted by scaleups and start-ups in developing repurposed drugs, rapid testing kits and vaccines. US remains the main Biotech Innovator

worldwide. And US is again casting a new net of Biotech Innovation, with huge investment pouring in from both public and private sources.

Biotech Trends: Shaping an Industry The novel innovative threads (read trends) of this net are, #AI (Artificial Intelligence): Start-ups are using Automation for discovering the treasure of new drugs, products, and processes and screening biomarkers. They are also using Image classification algorithm to detect different

38|November 2021|www.insightscare.com

trait canc

Furt anal leve plat

Wh anal a tra

h

,

are ent

traits (like crop disease symptoms from leaf images and cancer cells from medical scans) quickly.

Furthermore, start-ups are developing rapid diagnostics, analyzing microbiomes, and screening phenotypes by leveraging deep learning. Firms are also developing RNA platform which are guiding therapeutic development.

While others are identifying genetic markers which analyzes genomic data to understand genetic mechanism of a trait and then developing applications for novel drug

39|November 2021|www.insightscare.com

design, plant and livestock breeding, and diagnostic development. #Big Data and Analytics: This solution is enabling startups to tap into ever growing wealth of data coming in from omics tech, sensors integration, and IoT (Internet of Things) devices. This allows such firms to recruit patients and perform clinical trials on them more effectively. It can further find out suitable and safer treatment regimens as well as develop such regimens from disparate and unstructured data sources. They can also deploy such solutions to develop better feed, explore yet undiscovered microbes and improve varieties of crop and livestock.

Firms have developed a platform of genomic data analytics, by using a data library, to manage all data, samples, and modules, and run bioinformatic pipelines via cloud computing. #Gene Editing: Today instead of genetically modifying organisms, gene editing can precisely and efficiently edit genome, leveraging developments in CRISPR (as molecular scissors), and engineered nucleases to treat genetic disorders by editing (adding, replacing, and/or silencing) that gene. This can also create genome edited and transgenic plants, and animals.

There is also a next generation delivery tech, where chloroplast engineered traits are integrated into breeding processes suitable for engineering of metabolic pathways and modification of photosynthetic pathways. #Precision Medicine: Biotech start-ups are leveraging this solution to discover new drugs, identify novel targets, develop new drug delivery tech, and offer gene therapies.

There are also patient-centric, AI-powered gene therapies and drug development programs for non-invasive, precise, and personalized drug delivery mechanisms and gene therapy vectors. #Gene Sequencing: The reduced cost of gene sequencing has opened a wide range of applications like large cohort setups with extensive phenotyping, identification of pediatric disorders, personalized treatments, detecting microbes' presence (pathogens in clinical, beneficial soil microbes).

By using defined input sequences, start-ups are providing a solution for the quick and accurate identification of active COVID-19 infections. #Biomanufacturing: Utilizing biological systems it produces medical products and therapies, food and beverages, biomaterials, and specialty chemicals. To make

it inexpensive and scalable, startups are advancing recombinant production technologies, fermentation, and different cell culture.

The sustainability is enhanced by using biological raw materials. The industry's production models are also adopting machine learning and automation. Integrating Industry 4.0 models of automation and machine learning, startups are offering bioprocessing 4.0 to optimize each stage of the production process. #Bioprinting: By utilizing bioprinters which work with bio-inks developed from bio-based and biomaterials extracted from patients own cells, start-ups are enabling skin, bone, personalized medicines, and vascular grafts development. #Synthetic Biology: It offers increased standardization and reproducibility, allowing organisms manipulation at the gene networks level. A high yield of valuable biochemicals is provided by bacterial cell factories with applications in food, pharma, and materials. Moving beyond microbes, mammalian synthetic biology solutions are also in development. #Microfluidics: LOC or lab-on-a-chip devices needs microfluidics. These miniature labs facilitate POC or pointof-care diagnostics, quick and inexpensive testing of infectious diseases.

For diagnostics and environmental monitoring, start-ups are also developing paper-based microfluidics. The tech finds more biopharma applications in OOC or organ-on-a-chip devices, which simulate the physiology of organs/organ types on little chips. OOC systems are useful in disease modeling and drug screening. #Tissue Engineering: Due to developments in Bioprinting, Synthetic Biology and Microfluidics, Tissue engineering enables regenerative medicines, treatment of burns, and organ transplant by creating grafts of autologous tissues. To create sustainable alternatives to meat, leather and such animal products, start-ups are using tissue engineering widening its scope from limited biomedical applications.

Touching New Horizons: The most impactful trends from the list are AI (with 26% of the Biotech sector impacted), Big Data and Analytics (19%), Gene Editing (12%), and Precision medicine (10%).

The remaining 33% shows impact of the rest from Gene Sequencing to Tissue Engineering. Surely Biotech is rapidly touching new horizons of our modern life.

40|November 2021|www.insightscare.com

,

and

als n

nt-

are s p

ng, To

.

% of

%).

idly

Radiology

5

trends in

Imaging and

- by Meenakshi Singh, Co-founder and CEO, Synapsica

W

ith the growing popularity of minimally invasive procedures, there is a rising demand for accurate and efficient imaging technologies in both developed and developing countries. Radiology is one branch of diagnostic imaging that has kept up to date with the technological advances.

In this year's conference of Radiological Society of North America, a society formed by radiologists and health scientists around the world, the discussions mainly revolved around technology and its adoption. The general trend is that Healthcare as an industry is quick when it comes to adapting to innovations and radiology as a subfield leads this change.

Technological advancements, in the past few years, have led to major changes in the radiology industry and delivered crucial advantages to both the radiologists and the patients.

Many radiologists and radiology centers today are employing AI to assist them for faster, more accurate and subjective reports.

AI can easily spot a difference, as small as .001 micrometers, something which is not possible for the human eye to detect. It is because of this reason that radiologists and radiology centers that provide AI generated reports are seeing an uptick in the number of doctors approaching them for more reliable reports in the fastest possible time. In fact, when it comes to emergency and

trauma cases, a 3X jump has been seen for AI powered reporting requests over the last few years.

Other than the benefits of subjectivity, speed, remote reporting and more accuracy that AI is bringing in the radiology reporting, AI is also making it possible to detect a number of health issues precisely that are difficult to predict via traditional routes, like breast cancer, hemorrhagic stroke and lung cancer and spine degenerative diseases in advance and researches are on to detect more health issues that get missed especially at early stages.

Also, thanks to technology, more and more radiologists are able to work remotely and handle almost 3X more caseload.

Earlier, a lot of their time used to get lost in travelling to at least 3-4 centers in a day. It's a great support to the healthcare infrastructure in the country especially during the ongoing COVID pandemic when everyone must remain home to contain the spread.

With these ongoing advancements and the potential in the field, lets look at a few trends in the Radiology and Imaging industry that we can expect in 2022.

Trend #1 - AI in healthcare The pandemic accelerated the clinical adoption of AI. AI applications which were considered experimental applications pre-pandemic are now an integral part of

44|November 2021|www.insightscare.com

y

g

sica

ct a dict oke nce et

are oad. at

ain

e ging

About the Author Meenakshi Singh is the Co-founder and CEO at Synapsica, a health-tech platform for automating clinical and back-office radiology processes.

Synapsica's AI based solutions automatically generate clinical interpretations of radiology scans right after the image capture, without any radiologist intervention.

Meenakshi founded Synapsica in 2019 along with her co-founders, Kuldeep Singh Chauhan (CTO) and Dr Cherian (COO). She is responsible for fundraising, marketing and leads efforts for clinical validation and international regulatory compliance of the company's products. Under her aegis, Synapsica has helped in examining more than ten lakh patients.

Before starting her entrepreneurial journey, Meenakshi worked with multiple giants including - Google, LoanIQ, Manhattan associates and Goldman Sachs. During her four years stint at Goldman Sachs, Meenakshi was instrumental in building quant-fin data analytics solutions to detect and prevent fraud and manipulation in the US financial markets for fixed income securities and complex derivatives.

Time after time, Meenakshi has proven her tech acumen by implementing technology led changes in multiple companies.

Meenakshi is a postgraduate from IIM Ahmedabad and pursued B.E Computer Science from Manipal Institute of Technology. She is an ardent mountaineer, and her goal is to climb mountains 6000 meters and above.

45|November 2021|www.insightscare.com

AI-based image reconstruction techniques which makes it much more economical and uncomplicated to maintain.

Usage of advanced modalities has already increased by 43% and these advancements promise to further support this trend and further entrench diagnostic imaging in patient management protocols.

Hyperautomation India has only 10,000 radiologists for a billion people. This shortage means that radiologists work overtime to report.

However, technology has brought in an easier way for healthcare professionals to reduce their work by automating tasks. This is known as Hyperautomation.

Advanced technologies such as AI and ML automate numerous tasks bringing down the rate of error and allowing professionals to concentrate on important cases. In fact, it is expected that by 2024, organizations can bring down their operational costs by 30% through the combination of Hyperautomation and redesigned operational processes.

clinical reporting flows in several large-scale medical centers.

Trend #3 - Cross-discipline Collaboration Within Departments

AI can be used for various functions such as diagnosis, triaging and workflow automation. Many organizations are looking to integrate AI and accelerate its usage for diagnosis.

The internet has forever changed the healthcare landscape.

It allows data to be shared through web APIs, enabling cross-disciplinary collaboration and knowledge pooling.

With specialists collaborating with other healthcare experts, radiologists can apply integrated diagnostics using digital technology and move towards digitally reviewing images.

Trend #2 - Advances in imaging scanners and Hyperautomation

Trend #4 - Telemedicine and teleradiology

Imaging scanners today are providing much in-depth information about a patient's body. For instance, Siemens PCD (Photon Counting Detector) CT machine, which was unveiled at this year's RSNA conference, can provide substantially better contrast and spatial resolution for nearrealistic, cross-sectional images – a which means the system can capture even the most minute anatomical structures in a patient's body like- the smaller bronchi of the lungs or metastases in bones.

COVID-19 has created a need for telemedicine and teleradiology with even in-house panels reporting remotely.

Traditional in-house PACS are being replaced with imaging systems that allow for collaboration remotely. There is an increasing need in healthcare for professionals to be able to access the patients records remotely and from across departments.

This technology further reduces radiation exposure for patients while providing better diagnoses and hence opening up more use cases for CT scans. This is something which was unthinkable till just four years ago.

AI orchestrations are the newest addition to the suite of software solutions available for the radiology industry. AI orchestration provides organizations with intelligence to automate the daily operations of the business. This helps reduce repetitive tasks and the workload of professionals enabling them to focus on specific cases.

Similarly, MRI and x-rays motion scanners today are using

Trend #5 - AI Orchestration

46|November 2021|www.insightscare.com

it

ient

his .

ing

. In

pe.

rts, al s.

ely. ing n e to

AI

s